Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glufosfamide in metastatic pancreatic cancer
NCT00099294Phase 3Completed
- Sponsor
- Threshold Pharmaceuticals
- Start
- Sep 2004
- Primary completion
- Jan 2007
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, open-label trial of glufosfamide in pancreatic cancer (PC) (2 arms), sponsored by Threshold Pharmaceuticals. Primary endpoint: Overall Survival. Started Sep 2004; status: completed.
02
Drugs
glufosfamide
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00099294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00099294.